APO-LITHIUM CARBONATE 150 MG
LITHIUM CARBONATE : 150 MG · DIN 02242837 · APOTEX INC
Health Canada status: MARKETED
What is APO-LITHIUM CARBONATE?
APO-LITHIUM CARBONATE 150 MG contains LITHIUM CARBONATE : 150 MG. It is listed in the Health Canada Drug Product Database under DIN 02242837, held by APOTEX INC, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as marketed, status dated 12-Feb-2001. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02242837 |
|---|---|
| Brand name | APO-LITHIUM CARBONATE |
| Generic / active ingredient | LITHIUM CARBONATE : 150 MG |
| Manufacturer | APOTEX INC |
| Strength | 150 MG |
| Dosage form | CAPSULE |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N05AN01 LITHIUM |
| AHFS class | 28:28.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 12-Feb-2001 |
| Original market date | 2001-02-12 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code N05AN01 LITHIUM. 7 of 26 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| CARBOLITH | 150 MG | CAPSULE | BAUSCH HEALTH, CANADA INC. | MARKETED | DIN 00461733 |
| CARBOLITH | 600 MG | CAPSULE | BAUSCH HEALTH, CANADA INC. | MARKETED | DIN 02011239 |
| LITHANE | 150 MG | CAPSULE | SEARCHLIGHT PHARMA INC | MARKETED | DIN 02013231 |
| LITHANE | 300 MG | CAPSULE | SEARCHLIGHT PHARMA INC | MARKETED | DIN 00406775 |
| LITHMAX | 300 MG | TABLET (EXTENDED-RELEASE) | AA PHARMA INC | MARKETED | DIN 02266695 |
| PMS-LITHIUM CARBONATE - CAP 150MG | 150 MG | CAPSULE | PHARMASCIENCE INC | MARKETED | DIN 02216132 |
| APO-LITHIUM CARBONATE | 300 MG | CAPSULE | APOTEX INC | DORMANT | DIN 02242838 |
| CARBOLITH | 300 MG | CAPSULE | BAUSCH HEALTH, CANADA INC. | DORMANT | DIN 00236683 |
| DOM-LITHIUM CARBONATE | 150 MG | CAPSULE | DOMINION PHARMACAL | CANCELLED PRE MARKET | DIN 02231397 |
| DOM-LITHIUM CARBONATE | 300 MG | CAPSULE | DOMINION PHARMACAL | CANCELLED PRE MARKET | DIN 02231398 |
Who else supplies LITHIUM worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. LITHIUM appears in 7 registered pack listings across 6 markets, published on 5 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.